1.Harford JB. Breast-cancer early detection in low-income and middle-income countries: do what you can versus one size fits all. Lancet Oncol 2011; 12:306-312.
2.Nussbaumer S, Bonnabry P, Veuthey J, Fleury-Souverain S. Analysis of anticancer drugs: A review. Talanta 2011; 85:2265-2289.
3.Porter AC, Vaillancourt RR. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 1998; 16:1343-1352.
4.Mousavi SH, Tayarani-Najaran Z, Hersey P. Apoptosis: from signalling pathways to therapeutic tools. Iran J Basic Med Sci 2008; 11:121-142.
5.Aliabadi A, Eghbalian E, Kiani A. Synthesis and cytotoxicity evaluation of a series of 1,3,4-thiadiazole based compounds as anticancer agents. Iran J Basic Med Sci 2013; 16:1133-1138.
6.Madhusudan S, Ganesan TS. Tyrosine kinase inhibitors in cancer therapy. Clin Biochem 2004; 37:618-635.
7.Kemnitzer W, Kuemmerle J, Jiang S, Zhang H-Z, Sirisoma N, Kasibhatla S, et al. Discovery of 1-benzoyl-3-cyanopyrrolo[1,2-a]quinolines as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. Part 1: Structure-activity relationships of the 1- and 3-positions. Bioorg Med Chem Lett 2008; 18:6259-6264.
8.Albreht T, Mckee M, Alexe DM, Coleman MP, Martin-Moreno JM. Making progress against cancer in Europe in 2008. Eur J cancer 2008; 44:1451-1456.
9.Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18:581-592.
10.Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer Statistics, 2006. Cancer J Clin 2006; 56:106-130.
11.Bhuran HA, Kini SJ. Synthesis, anticancer activity and docking of some substituted benzothiazoles as tyrosine kinase inhibitors. J Mol Graph Model 2010; 29:32-37.
12.Siddiqui N, Faiz Arshad M, Ahsan W, Shamsher Alam M. Thiazoles: a valuable insight into the recent advances and biological activities. Int J Pharm Sci Drug Res 2009; 1:136-143.
13.De S, Adhikari S, Tilak-Jain J, Menon VP, Devasagayam TPA. Antioxidant activity of an aminothiazole compound: possible mechanism. Chem-Biol Interact 2008; 173:215-223.
14.Zaharia V, Ignat A, Palibroda N, Ngameni B, Kuete V, Fokunang CN, et al. Synthesis of some p-toluenesulfonyl-hydrazinothiazoles and their anticancer activity. Eur J Med Chem 2010; 45:5080-5085.
15.Aliabadi A, Shamsa F, Ostad SN, Emami S, Shafiee A, Davoodi J, et al. Synthesis and biological evaluation of 2-Phenylthiazole-4-carboxamide derivatives as anticancer agents. Eur J Med Chem 2010; 11:5384-5389.
16.Nazari Tarhan H, Hosseinzadeh L, Aliabadi A, Babak Gholamine, Foroumadi A. Cytotoxic and apoptogenic properties of 2-phenylthiazole-4-carboxamide derivatives in human carcinoma cell lines. J Rep Pharm Sci 2012; 1:1-7.
17.Aliabadi A, Foroumadi A, Safavi M, Kaboudian Ardestani S. Synthesis, molecular docking and cytotoxicity evaluation of 2-(4-substituted-benzyl)isoindoline-1,3-dione derivatives as anticancer agents. J Rep Pharm Sci 2012; 1:19-22.
18.Aliabadi A, Foroumadi A, Safavi M, Ardestani S. Synthesis, cytotoxicity assessment, and molecular docking of 4-Substituted-2-p-thiazole derivatives as probable c-Src and erb tyrosine kinase inhibitors. Croat Chem Acta 2013; 86: in press.
19.Mahmoodi M, Aliabadi A, Emami S, Safavi M, Rjabalian S, Mohagheghi MA, et al. Synthesis and in-vitro cytotoxicity of poly-functionalized 4-(2-arylthiazole-4-yl)-4H-chromenes. Arch Pharm Chem Life Sci 2010; 343:411-416.
20.Stankova IG, Videnov GI, Golovinsky EV, Jung G. Synthesis of thiazole, imidazole and oxazole containing amino acids for peptide backbone modification. J Peptide Sci 1999; 5:392-398.
21.Aliabadi A, Andisheh S, Tayarani-Najaran, Z, Tayarani-Najaran M. 2-(4-Fluorophenyl)-N-phenylacetamide derivatives as anticancer agents: synthesis and in vitro cytotoxicity evaluation. Iran J Pharm Res 2013; 3:267-271.
22.Aliabadi A, Hasanvand Z, Kiani A, Mirabdali SS. Syn-thesis and in vitro cytotoxicity assessment of N-(5-(Benzylthio)-1,3,4-thiadiazol-2-yl)-2-(4-(trifluoro- methyl)phenyl) aceta-mide with potential anticancer activity. Iran J Pharm Res, 2013; 4:687-693.